Analyst Price Targets — IDXX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 28, 2026 12:16 pm | Andrea Alfonso | UBS | $640.00 | $569.17 | TheFly | Idexx Laboratories price target lowered to $640 from $730 at UBS |
| February 9, 2026 11:54 am | — | Piper Sandler | $750.00 | $644.61 | TheFly | Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler |
| February 5, 2026 10:41 am | Glen Santangelo | Barclays | $800.00 | $642.94 | TheFly | Idexx Laboratories price target lowered to $800 from $850 at Barclays |
| February 3, 2026 12:07 pm | Andrea Alfonso | UBS | $730.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $730 from $750 at UBS |
| February 3, 2026 2:07 am | — | BTIG | $800.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $800 from $830 at BTIG |
| December 8, 2025 9:26 pm | Glen Santangelo | Barclays | $850.00 | $706.65 | TheFly | Idexx Laboratories initiated with an Overweight at Barclays |
| November 4, 2025 1:42 pm | — | Morgan Stanley | $805.00 | $721.04 | TheFly | Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley |
| November 4, 2025 12:37 pm | — | UBS | $750.00 | $722.94 | TheFly | Idexx Laboratories price target raised to $750 from $710 at UBS |
| November 4, 2025 12:23 pm | — | BTIG | $830.00 | $722.94 | TheFly | Idexx Laboratories price target raised to $830 from $785 at BTIG |
| November 4, 2025 10:06 am | Keith Devas | Jefferies | $830.00 | $722.94 | StreetInsider | IDEXX Laboratories (IDXX) PT Raised to $830 at Jefferies |
Latest News for IDXX
Data centers receive sharp criticism for their high water usage, but the impact on the broader water industry and for investors is also about infrastructure bottlenecks, regulation, and emerging technologies, among other things. Utilities companies must navigate significant changes when hyperscalers enter their territory—in some cases, a new data center operator may immediately become one of the largest customers in…
ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Alcon (ALC) or Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of…
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.